Cover Image
市場調查報告書

特發性肺纖維化:開發中產品分析

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232804
出版日期 內容資訊 英文 260 Pages
訂單完成後即時交付
價格
Back to Top
特發性肺纖維化:開發中產品分析 Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 260 Pages
簡介

特發性肺纖維化(IPF),是肺的孤立性進行性疾病。有乾咳、呼吸急促(特別是運動中/運動後)、持續性的疲勞、體重減少等症狀。治療包含抗氧化劑、生物學的反應調節劑、抗纖維化劑、抗凝劑等。

本報告提供特發性肺纖維化治療藥的開發情形調查分析、開發中產品的概要、臨床實驗各階段的產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

特發性肺纖維化概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

各調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

各調查中的產品:各大學/研究機關

開發治療藥的企業

  • AdAlta Pty Ltd.
  • Aeolus Pharmaceuticals, Inc.
  • AnaptysBio, Inc.
  • Auspex Pharmaceuticals, Inc.
  • Biogen Idec Inc.
  • Bioneer Corporation
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Carolus Therapeutics, Inc.
  • Celgene Corporation
  • Chong Kun Dang Pharmaceutical Corp.
  • Compugen Ltd.
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Five Prime Therapeutics, Inc.
  • GenKyoTex S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • HanAll Biopharma Co., Ltd.
  • Histocell S.L.
  • iBio, Inc.
  • ImmuneWorks, LLC
  • Inventiva SAS
  • Kadmon Corporation, LLC
  • Kasiak Research Pvt. Ltd.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lanthio Pharma B.V.
  • LTT Bio-Pharma Co., Ltd.
  • MedImmune, LLC
  • Moerae Matrix, Inc.
  • MSM Protein Technologies, Inc.
  • Pacific Therapeutics Ltd.
  • Pharmaxis Limited
  • Progenra, Inc.
  • Promedior, Inc.
  • ProMetic Life Sciences Inc.
  • Pulmatrix, Inc.
  • Sanofi
  • Therametrics holding AG

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BMS-986020
  • BOT-191
  • CC-539
  • CC-90001
  • CGEN-25009
  • CKD-942
  • CT-2009
  • FG-3019
  • FPA-008
  • GKT-137831
  • GKT-901
  • HC-016
  • HL-156FIB
  • HR-017
  • IBIOCFB-03
  • ICG-001
  • interferon gamma-1b
  • IVA-337
  • IW-001
  • KBP-7018
  • KD-025
  • lebrikizumab
  • LP2
  • LT-0011
  • LTI-03
  • MMI-0100
  • Monoclonal Antibody for Idiopathic Pulmonary Fibrosis
  • MSM-735
  • NAS-911
  • nintedanib
  • omipalisib
  • PBF-1250
  • PBI-4050
  • pirfenidone
  • PRM-151
  • PUR-1500
  • PXS-25
  • PXS-4820
  • PXS-64
  • Refacell-IPF
  • RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis
  • SAR-156597
  • SD-560
  • simtuzumab
  • Small Molecule 2 for Chronic Respiratory Diseases
  • Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis
  • Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis
  • Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis
  • SPL-334
  • Stem Cell Therapy for Idiopathic Lung Fibrosis
  • Stem Cell Therapy for Lung Fibrosis
  • STX-100
  • TD-139
  • tipelukast
  • tralokinumab
  • vismodegib
  • ZL-2102

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8608IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 49 and 8 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively for Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Idiopathic Pulmonary Fibrosis Overview
  • Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies
  • Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Idiopathic Pulmonary Fibrosis - Pipeline Products Glance
  • Idiopathic Pulmonary Fibrosis - Products under Development by Companies
  • Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
  • Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
  • Drug Profiles
  • Idiopathic Pulmonary Fibrosis - Dormant Projects
  • Idiopathic Pulmonary Fibrosis - Discontinued Products
  • Idiopathic Pulmonary Fibrosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2016
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by ARMO Biosciences, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Pharma Corp., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by GNI Group Ltd., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Immunomet Therapeutics, Inc. , H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Novartis AG, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Nuevolution AB, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Samumed LLC, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by SPR Biosciences LLC, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H2 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Idiopathic Pulmonary Fibrosis - Dormant Projects, H2 2016
  • Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2016
  • Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2016
  • Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..3), H2 2016
  • Idiopathic Pulmonary Fibrosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2016
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top